{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:15:51Z","timestamp":1790712951997,"version":"4.1.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,2,28]],"date-time":"2019-02-28T00:00:00Z","timestamp":1551312000000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001711","name":"ETH Z\u00fcrich, the Swiss National Science Foundation","doi-asserted-by":"publisher","award":["310030B_163479\/1"],"award-info":[{"award-number":["310030B_163479\/1"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001808","name":"the Swiss Federal Commission for Technology and Innovation","doi-asserted-by":"publisher","award":["17072.1"],"award-info":[{"award-number":["17072.1"]}],"id":[{"id":"10.13039\/501100001808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["607603"],"award-info":[{"award-number":["607603"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Laboratory for Animal Model Pathology,"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biotechnology"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.jbiotec.2018.02.004","type":"journal-article","created":{"date-parts":[[2018,2,10]],"date-time":"2018-02-10T12:13:48Z","timestamp":1518264828000},"page":"29-36","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads"],"prefix":"10.1016","volume":"271","author":[{"given":"Anja Sophie","family":"Schmid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Tintor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dario","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbiotec.2018.02.004_bib0005","doi-asserted-by":"crossref","first-page":"2702","DOI":"10.1073\/pnas.93.7.2702","article-title":"Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins","volume":"93","author":"Becker","year":"1996","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.cytogfr.2014.07.011","article-title":"G-CSF: from granulopoietic stimulant to bone marrow stem cell mobilizing agent","volume":"25","author":"Bendall","year":"2014","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0015","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.drudis.2015.10.012","article-title":"Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions","volume":"21","author":"Bootz","year":"2016","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0020","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1097\/MIB.0000000000000851","article-title":"Antibody-based targeted delivery of interleukin-22 promotes rapid clinical recovery in mice with DSS-induced colitis","volume":"22","author":"Bootz","year":"2016","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0025","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1002\/art.24441","article-title":"Important role of interleukin-3 in the early phase of collagen-induced arthritis","volume":"60","author":"Bruhl","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0030","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nrc.2016.52","article-title":"Neutrophils in cancer: neutral no more","volume":"16","author":"Coffelt","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0035","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.exphem.2004.01.012","article-title":"Enhanced circulating half-life and hematopoietic properties of a human granulocyte colony-stimulating factor\/immunoglobulin fusion protein","volume":"32","author":"Cox","year":"2004","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ijc.20952","article-title":"Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy","volume":"116","author":"Ebbinghaus","year":"2005","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/stem.150327","article-title":"IL-3 in the clinic","volume":"15","author":"Eder","year":"1997","journal-title":"Stem Cells"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0050","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.18632\/oncotarget.1853","article-title":"The immunocytokine NHS-IL12 as a potential cancer therapeutic","volume":"5","author":"Fallon","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0055","first-page":"1730","article-title":"A diphtheria toxin-interleukin 3 fusion protein is cytotoxic to primitive acute myeloid leukemia progenitors but spares normal progenitors","volume":"62","author":"Feuring-Buske","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0060","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/sj.leu.2401743","article-title":"Diphtheria toxin fused to human interleukin-3 is toxic to blasts from patients with myeloid leukemias","volume":"14","author":"Frankel","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0065","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1016\/j.juro.2010.07.030","article-title":"The immunocytokine F8-IL2 improves the therapeutic performance of sunitinib in a mouse model of renal cell carcinoma","volume":"184","author":"Frey","year":"2010","journal-title":"J. Urol."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0070","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.pep.2013.09.001","article-title":"Polyethyleneimine-based transient gene expression processes for suspension-adapted HEK-293E and CHO-DG44 cells","volume":"92","author":"Hacker","year":"2013","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0075","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1023\/A:1020917732218","article-title":"Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys","volume":"19","author":"Halpern","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0080","doi-asserted-by":"crossref","first-page":"12008","DOI":"10.1073\/pnas.1402783111","article-title":"Antibody-based delivery of IL4 to the neovasculature cures mice with arthritis","volume":"111","author":"Hemmerle","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0085","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/ijc.28359","article-title":"The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer","volume":"134","author":"Hemmerle","year":"2014","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0090","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1158\/2326-6066.CIR-13-0182","article-title":"The dose-dependent tumor targeting of antibody-IFNgamma fusion proteins reveals an unexpected receptor-trapping mechanism in vivo","volume":"2","author":"Hemmerle","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0095","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/bjc.2013.421","article-title":"The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity","volume":"109","author":"Hemmerle","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0100","doi-asserted-by":"crossref","first-page":"6444","DOI":"10.1073\/pnas.90.14.6444","article-title":"\"Diabodies\": small bivalent and bispecific antibody fragments","volume":"90","author":"Holliger","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0105","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.1073\/pnas.85.16.5879","article-title":"Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli","volume":"85","author":"Huston","year":"1988","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0110","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1158\/0008-5472.CAN-07-0283","article-title":"The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis","volume":"67","author":"Kaspar","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0115","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1111\/imr.12391","article-title":"Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site","volume":"270","author":"Kiefer","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0120","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.abb.2012.03.001","article-title":"Antibody-cytokine fusion proteins","volume":"526","author":"Kontermann","year":"2012","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0125","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/ard.44.8.549","article-title":"Cellular immunohistopathology of acute, subacute, and chronic synovitis in rheumatoid arthritis","volume":"44","author":"Konttinen","year":"1985","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0130","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.4049\/jimmunol.1500907","article-title":"IL-3 decreases cartilage degeneration by downregulating matrix metalloproteinases and reduces joint destruction in osteoarthritic mice","volume":"196","author":"Kour","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0135","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"Mossner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0140","series-title":"Janeway\u2019s Immunobiology","author":"Murphy","year":"2012"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0145","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.coi.2016.03.006","article-title":"Immunocytokines for cancer treatment: past, present and future","volume":"40","author":"Neri","year":"2016","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0150","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1002\/1097-0142(19910515)67:10+<2712::AID-CNCR2820671708>3.0.CO;2-O","article-title":"Interleukin-3. Biologic effects and clinical impact","volume":"67","author":"Oster","year":"1991","journal-title":"Cancer"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0155","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.drudis.2012.01.007","article-title":"Immunocytokines: a novel class of potent armed antibodies","volume":"17","author":"Pasche","year":"2012","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jbiotec.2011.04.003","article-title":"Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7","volume":"154","author":"Pasche","year":"2011","journal-title":"J. Biotechnol."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0165","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s00259-010-1446-9","article-title":"Tumour-targeting properties of antibodies specific to MMP-1A, MMP-2 and MMP-3","volume":"37","author":"Pfaffen","year":"2010","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0170","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0378-1097(03)00473-7","article-title":"G-CSF immunotherapy for treatment of acute disseminated murine melioidosis","volume":"224","author":"Powell","year":"2003","journal-title":"FEMS Microbiol. Lett."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0175","doi-asserted-by":"crossref","first-page":"10948","DOI":"10.1158\/0008-5472.CAN-07-1436","article-title":"The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases","volume":"67","author":"Rybak","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0180","doi-asserted-by":"crossref","first-page":"R142","DOI":"10.1186\/ar2814","article-title":"Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis","volume":"11","author":"Schwager","year":"2009","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0185","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/sj.leu.2400607","article-title":"Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications","volume":"11","author":"Spiekermann","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0190","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.4049\/jimmunol.1002691","article-title":"IL-3 attenuates collagen-induced arthritis by modulating the development of Foxp3+ regulatory T cells","volume":"186","author":"Srivastava","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0195","doi-asserted-by":"crossref","first-page":"983698","DOI":"10.1155\/2015\/983698","article-title":"Neutrophils in cancer: two sides of the same coin","volume":"2015","author":"Uribe-Querol","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0200","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/ijc.23408","article-title":"A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo","volume":"122","author":"Villa","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0205","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.immuni.2016.06.025","article-title":"Type 2 interleukin-4 receptor signaling in neutrophils antagonizes their expansion and migration during infection and inflammation","volume":"45","author":"Woytschak","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0210","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/rheumatology\/keq045","article-title":"Neutrophil function in inflammation and inflammatory diseases","volume":"49","author":"Wright","year":"2010","journal-title":"Rheumatology (Oxf.)"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0215","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/nrrheum.2014.80","article-title":"The multifactorial role of neutrophils in rheumatoid arthritis","volume":"10","author":"Wright","year":"2014","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0220","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1182\/blood-2009-10-250555","article-title":"Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma","volume":"115","author":"Xuan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jbiotec.2018.02.004_bib0225","first-page":"1070","article-title":"Carbohydrate does not modulate the in vivo effects of injected interleukin-3","volume":"22","author":"Ziltener","year":"1994","journal-title":"Exp. Hematol."}],"container-title":["Journal of Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165618300488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168165618300488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T12:48:54Z","timestamp":1759150134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168165618300488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":45,"alternative-id":["S0168165618300488"],"URL":"https:\/\/doi.org\/10.1016\/j.jbiotec.2018.02.004","relation":{},"ISSN":["0168-1656"],"issn-type":[{"value":"0168-1656","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel antibody-cytokine fusion proteins featuring granulocyte-colony stimulating factor, interleukin-3 and interleukin-4 as payloads","name":"articletitle","label":"Article Title"},{"value":"Journal of Biotechnology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbiotec.2018.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}